By inhibiting interleukin-8-mediated neutrophil signaling, LDX aims to attenuate inflammatory cascades that drive autoimmune β-cell destruction in newly diagnosed type 1 diabetes mellitus (T1DM) (148). This evidence concerns the gene CXCL8 and type 1 diabetes mellitus.